



Trabajo Original

Otros

Five-day preoperative immunonutrition in patients undergoing major surgery for gastrointestinal cancer — A cost-effectiveness analysis under the Brazilian healthcare system perspective

Inmunonutrición preoperatoria durante 5 días en pacientes sometidos a cirugía mayor por cáncer gastrointestinal: un análisis de coste-efectividad desde la perspectiva del sistema de salud brasileño

Pedro E. P. Filho¹, Guilherme A. G. Ravanini¹, Ana C. P. Ribeiro-Pereira², Lucas Fahham², Roberta A. Fernandes², Victoria M. R. Pagliosa³, Valeria A. S. Rosenfeld³

¹Universidade Federal do Estado do Rio de Janeiro (UNIRIO). Rio de Janeiro, Rio de Janeiro. Brazil. ²ORIGIN Health. São Paulo, São Paulo. Brazil. ³Nestlé Health Science. São Paulo, São Paulo. Brazil

Abstract

Objectives: this study aims to evaluate the cost-effectiveness of 5-day preoperative enteral or oral immunonutrition in patients undergoing major surgery for gastrointestinal cancer, under the Brazilian Unified Health System (*Sistema Único de Saúde* – SUS) perspective. A budget impact analysis was also performed.

Methods: a decision tree model was built to compare enteral or oral immunonutrition with the standard diet, considering a time horizon of 5 + 30 days. To determine the efficacy outcomes, studies using 5-day preoperative immunonutrition were retrieved from a previously published meta-analysis. New combined estimates for the occurrence of infectious complications, non-infectious complications, length of stay, and 30-day mortality were calculated using studies with a 5-day period intervention. Treatment strategies were compared using the incremental cost-effectiveness ratio (ICER). Costs were reported in Brazilian reais (BRL) and euros (EUR).

Results: results combined through the meta-analysis showed that the occurrence of infectious complications was 17.2 % (65/378) and 28.8 % (99/344) for the immunonutrition and the control group, respectively (OR = 0.46; 95 % CI = 0.28-0.78; $p = 0.003$). Considering total costs by procedure, estimates of 930.56 BRL/151.31 EUR (267.75 BRL/43.54 EUR due to immunonutrition and 662.81 BRL/107.77 EUR due to infectious complications management) and 1,109.29 BRL/180.37 EUR (0.0 BRL/EUR due to standard diet and 1,109.29 BRL/180.37 EUR due to infectious complications management) were observed for immunonutrition and standard diet groups, respectively. Cost-effectiveness analysis showed that immunonutrition reduced the occurrence of infectious complications (-12 %) with lower costs (-178.73 BRL/-29.06 EUR). Total savings over 5 years was approximately 5 million BRL/817,352 EUR.

Conclusion: 5-day preoperative enteral or oral immunonutrition not only has a positive clinical impact for patients undergoing major surgery for gastrointestinal cancer but can also generate substantial reductions in costs for SUS.

Keywords:

Cost-effectiveness analysis.
Immunonutrition diet.
Gastrointestinal neoplasms.
Surgical procedures,
operative.

Received: 16/10/2024 • Accepted: 17/07/2025

Authors' contribution: P. E. P. F.: conceptualization, validation, writing-review and editing. G. A. G. R.: conceptualization, validation, writing-review and editing. A. C. P. R. P.: methodology, writing-original draft preparation. L. F.: formal analysis, methodology, writing-review and editing. R. A. F.: methodology, writing-original draft preparation. V. M. R. P.: conceptualization, methodology, writing-review and editing. V. A. S. R.: conceptualization, funding acquisition, methodology, writing-review and editing.

Conflicts of interest: V. M. R. P. and V. A. S. R. are full-time employees of Nestlé. L. F., A. C. P. R. P. and R. A. F. work in a consultancy that provides services to Nestlé and received financial support to participate in this work. P. E. P. F. and G. A. G. R. declare no conflict of interest.

Artificial intelligence: The authors declare not to have used artificial intelligence (AI) or any AI-assisted technologies in the elaboration of the article.

Filho PEP, Ravanini GAG, Ribeiro-Pereira ACP, Fahham L, Fernandes RA, Pagliosa VMR, Rosenfeld VAS. Five-day preoperative immunonutrition in patients undergoing major surgery for gastrointestinal cancer — A cost-effectiveness analysis under the Brazilian healthcare system perspective. *Nutr Hosp* 2025;42(5):1039-1046

DOI: <http://dx.doi.org/10.20960/nh.05553>

Correspondence:

Valeria A. S. Rosenfeld. Nestlé Health Science. Rua Doutor Rubens Gomes Bueno, 691, Edif Torre Sigma, Andar 19 ao 28. São Paulo, São Paulo. Brazil
e-mail: valeria.rosenfeld@br.nestle.com

Resumen

Objetivos: este estudio tiene como objetivo evaluar la relación coste-efectividad de la inmunonutrición enteral u oral preoperatoria durante 5 días en pacientes sometidos a cirugía mayor por cáncer gastrointestinal desde la perspectiva del Sistema Único de Salud (SUS) de Brasil. También se realizó un análisis del impacto presupuestario.

Métodos: se construyó un modelo de árbol de decisión para comparar la inmunonutrición enteral u oral con la dieta estándar, considerando un horizonte temporal de 5 + 30 días. Para determinar los resultados de eficacia, se recuperaron estudios que utilizaron inmunonutrición preoperatoria de 5 días a partir de un metaanálisis previamente publicado. Se calcularon nuevas estimaciones combinadas para la ocurrencia de complicaciones infecciosas, complicaciones no infecciosas, duración de la hospitalización y mortalidad a los 30 días utilizando estudios con una intervención de 5 días. Las estrategias de tratamiento se compararon utilizando la razón de coste-efectividad incremental (RCEI). Los costes se informaron en reales brasileños (BRL) y euros (EUR).

Resultados: los resultados combinados a través del metaanálisis mostraron que la ocurrencia de complicaciones infecciosas fue del 17,2 % (65/378) y del 28,8 % (99/344) para el grupo de inmunonutrición y el grupo de control, respectivamente (OR = 0,46; IC 95 % = 0,28-0,78; $p = 0,003$). Al considerar los costes totales por procedimiento, se observaron estimaciones de 930,56 BRL/151,31 EUR (267,75 BRL/43,54 EUR debido a la inmunonutrición y 662,81 BRL/107,77 EUR debido al manejo de complicaciones infecciosas) y 1.109,29 BRL/180,37 EUR (0,0 BRL/EUR debido a la dieta estándar y 1.109,29 BRL/180,37 EUR debido al manejo de complicaciones infecciosas) para los grupos de inmunonutrición y dieta estándar, respectivamente. El análisis de coste-efectividad mostró que la inmunonutrición redujo la ocurrencia de complicaciones infecciosas (-12 %) con costes más bajos (-178,73 BRL/-29,06 EUR). El ahorro total en 5 años fue de aproximadamente 5 millones de BRL/817.352 EUR.

Conclusión: la inmunonutrición enteral u oral preoperatoria durante 5 días no solo tiene un impacto clínico positivo para los pacientes sometidos a cirugía mayor por cáncer gastrointestinal, sino que también puede generar reducciones sustanciales en los costes para el SUS.

Palabras clave:

Análisis de coste-efectividad. Dieta de inmunonutrición. Neoplasias gastrointestinales. Procedimientos quirúrgicos operativos.

INTRODUCTION

According to the European Society for Clinical Nutrition and Metabolism (ESPEN) and the American Society for Enhanced Recovery (ASER) guidelines, nutritional deficiencies in individuals with indication for surgery appears as an independent risk factor for the occurrence of postoperative complications such as infection, increase in the recovery time, length of hospital stay, mortality and hospital costs (1-3).

Based on the approach developed and accepted within the past two decades, apart from the standard nutrition, an enriched nutrition formula with some key nutrients is used to enhance patients' immunity (4). Nutrients such as arginine, nucleotides, and omega-3 fatty acids are known to play a key role in these steps within the complex structure of the inflammatory response (5). Several studies have shown that the immunonutrition improves immune responses, controls inflammatory changes, modulates the synthesis of acute-phase proteins, increases the intestinal oxygenation and barrier function after injury; furthermore, it also reduces septic morbidity and length of hospital stay (6,7).

The ESPEN guideline, published in 2021, recommends perioperative immunonutrition in patients with malnutrition and in those at nutritional risk. Perioperative immunonutrition should also be initiated if it is anticipated that the patient will be unable to eat for more than five days in the perioperative period. It is also indicated in patients expected to have low oral intake and who cannot maintain above 50 % of the recommended intake for more than seven days. Patients at severe nutritional risk shall receive immunonutrition prior to major surgery even if operations including those for cancer has to be delayed. A period of 7-14 days may be appropriate. Immune-modulating oral nutritional supplements including arginine, omega-3 fatty acids and nucleotides can be preferred and administered for five to seven days preoperatively preferably for malnourished individuals, but guideline does not contraindicate the practice for those at nutritional risk (1).

The impact of oral or enteral immunonutrition in patients undergoing major surgery for gastrointestinal cancer was previously

assessed in several meta-analysis, the last one conducted by Adiamah et al. (2019) (8-10). Preoperative immunonutrition significantly reduces infectious complications and leads to a shorter length of stay (8). In addition, the use of immunonutrition among patients undergoing surgical procedures, used either as pre, peri or postoperative strategy, shows to be cost-effective and able to reduce resource utilization and costs (11-15). Considering patients with the diagnosis of gastrointestinal neoplasms, the strategy has also shown to be cost-effective, however, only one study has assessed specifically the use of preoperative immunonutrition to date (11-13,16).

Gastrointestinal cancers impose an important burden to the whole society. For the triennium 2023-2025, it was estimated that 483,000 new cases of cancer, excluding non-melanoma, will occur in Brazil, of which at least 12 % will be gastrointestinal neoplasms (17). Torres et al. (2010) conducted a study to estimate hospital admission rates for colorectal cancer in the Brazilian Public Health System. Considering the 1996-2008 period, hospitalization costs rose from 16.5 million American dollars (USD) to 33.5 million USD (31.870.225 euros [EUR]) (18).

Given the burden of gastrointestinal cancer and the clinical benefits of the use of immunonutrition in this group, understanding the economic impact of its use seems to be meaningful for the decision-making process. Hence, we conducted a cost-effectiveness study of 5-day preoperative enteral or oral immunonutrition in patients undergoing major surgery for gastrointestinal cancer. In addition, a budget impact analysis under the perspective of Brazilian Unified Health System (*Sistema Único de Saúde* – SUS) was performed.

MATERIALS AND METHODS

STUDY DESIGN

An economic evaluation was conducted aiming to determine the cost-effectiveness of 5-day preoperative enteral or oral

immunonutrition in patients undergoing major surgery for gastrointestinal cancer, including the upper and lower digestive tract, under the perspective of the SUS. Efficacy was assessed using data from the meta-analysis published by Adiamah et al. (2019), while costs were estimated through specialist physician's opinion and available price sources (8). The need for appreciation by an ethics committee or an informed consent was waived for this study since only previously published and publicly available data was used.

EFFECTIVENESS DATA AND META-ANALYSIS

The study was conducted based on the meta-analysis published by Adiamah et al. (2019). In the published review, the authors conducted searches at Embase, Cochrane Collaboration and Medline between 2000 and 2018 and included prospective randomized controlled trials reporting at least one relevant clinical outcomes in adults undergoing surgical procedure for gastrointestinal cancer (8). Considering that our aim was to assess cost-effectiveness of 5-day preoperative immunonutrition, the studies assessing such period were selected and combined estimates for the occurrence of infectious complications, non-infectious complications, length of stay, and 30-day mortality were calculated. Thus, the number of patients presenting each outcome in the groups of interest, as well as mean length of stay, was extracted from the studies included in the review.

To ensure that all relevant studies were included, electronic searches were carried out until August/2020 in the following databases: MEDLINE/PubMed, The Cochrane Library, Latin American and Caribbean Health Sciences Literature (LILACS), and Centre for Reviews and Dissemination (CRD). Further, they were complemented through manual searches of references from the originally identified articles and grey literature search. The complete search strategies used for each database are shown in the supplementary material (Suppl. Table I - <https://www.nutricionhospitalaria.org/files/9272/ADMA1-05553-03.pdf>). No additional eligible studies were found.

For the meta-analysis, continuous outcomes were summarized as weighted mean differences (WMDs), while dichotomous outcomes were summarized as odds ratios (ORs), with 95 % confidence intervals (CIs). The heterogeneity was assessed using I^2 statistic, defined as low (0-40 %), moderate (40-75 %) and high (> 75 %). The risk of bias of individual studies was

assessed using the risk of bias 2 assessment form (Suppl. Fig. 1 - <https://www.nutricionhospitalaria.org/files/9272/ADMA1-05553-03.pdf>) and publication bias was assessed by the symmetry of the funnel plots for all outcomes. A random effects model was used, considering a more conservative approach (19). The analysis was performed using the software RevMan, version 5.4 (20).

MODEL CHARACTERISTICS

A cost-effectiveness analysis was performed to compare enteral or oral immunonutrition with the standard diet of patients undergoing major gastrointestinal cancer surgery. The standard diet was defined as a preoperative diet without supplementation or with isocaloric and isonitrogen supplementation. The model was defined as a decision tree in which patients undergoing major procedures could receive immunonutrition or a standard diet. These patients were evaluated for infectious complications 30 days after surgery (Suppl. Fig. 2 - <https://www.nutricionhospitalaria.org/files/9272/ADMA1-05553-03.pdf>). A time horizon of 5 + 30 days was considered, with five days for pre-surgical enteral/oral immunonutrition and up to 30 days after surgery to assess the occurrence of complications. There was no need to apply a discount rate as the time horizon was less than one year. The economic evaluation was conducted from the SUS perspective.




Figure 1. Forest plot showing the pooled odds ratio for the occurrence of infectious complications.

Table I. Pooled results obtained from the meta-analysis

	Immunonutrition % (n/N)	Control % (n/N)	OR (95 % CI)	p-value
Infectious complications	17.2 (65/378)	28.8 (99/344)	0.46 (0.28; 0.78)	0.003
Non-infectious complications	16.4 (62/378)	18.0 (62/344)	0.93 (0.59; 1.45)	0.74
Length of stay – mean days	-	-	-2.42 (-3.72; -1.12)	< 0.001
Mortality	0.4 (1/272)	0.4 (1/263)	1.00 (0.06; 16.21)	> 0.99




Figure 2. Tornado diagram. A. Values presented in Brazilian reals (BRL). B. Values presented in euros (EUR).

OUTCOME MEASUREMENT

The occurrence of infectious complications was defined as the primary study outcome. Secondary outcomes were non-infectious complications, length of stay, and 30-day mortality. Economic outcomes considered direct medical costs, including medical resources used directly for patient care, immunonutrition costs, and infectious complications treatment. Indirect costs, such as those related to patient productivity loss because of the illness, were not considered in this analysis, as they are not consistent with the adopted perspective. Treatment strategies were compared using the incremental cost-effectiveness ratio (ICER), defined as the ratio of the difference in costs to the difference in effectiveness between treatment strategies (Equation I).

EQUATION I. INCREMENTAL COST-EFFECTIVENESS RATIO

$$ICER = \frac{Cost_{Immunonutrition} - Cost_{Standard\ diet}}{Effectiveness_{Immunonutrition} - Effectiveness_{Standard\ diet}}$$

ICER: incremental cost-effectiveness ratio.

RESOURCES AND COST ESTIMATION

A dosage of 1000 mL per day for five days was adopted to calculate the immunonutrition cost. The price for 1000 mL of the product was defined according to the expected reimbursement value for the Brazilian public market, its variation was evaluated in sensitivity analysis. The comparator, standard diet, has no cost, as there is currently no reimbursement for pre-surgical supplementation with immunonutrition or any other specific diet in the universal health system in Brazil. The microcosting strategy defined infectious complications cost, as detailed reported in supplementary table II (<https://www.nutricionhospitalaria.org/files/9272/ADMA1-05553-03.pdf>). The use of resources was defined base on a specialist physician's opinion and precified using public reimbursement tables from the Brazilian universal health system (Brazilian Universal Health System's Table of Procedures, Medications and Special Materials – SIGTAP) — the great uncertainties in this cost definition led to its evaluation by sensitivity analysis. The analysis included only the relevant costs that could differ between treatment groups (nutritional intervention and infectious complication costs). Other costs, such as hospitalization costs or non-infectious complications, were assumed to be the same between groups and were not considered in the analysis. All costs were reported in Brazilian Real (BRL) and Euro (EUR), considering an exchange rate of 1 EUR = 6.15 BRL (average rate between September 6, 2024, and December 2, 2024).

ANALYTICAL METHODS

The economic evaluation was defined from a decision tree modelling (Suppl. Fig. 2 - <https://www.nutricionhospitalaria.org/files/9272/ADMA1-05553-03.pdf>). Deterministic and probabilistic sensitivity analyses evaluate the model's uncertainties. These methods assess how changes in input parameters affect the

Table II. Cost-effectiveness analysis results

	Immunonutrition	Standard diet	Incremental
Total cost (by procedure) (BRL/EUR)	930.56/146.05	1,109.29/174.10	-178.73/-28.05
Immunonutrition (BRL/EUR)	267.75/42.02	0.00	267.75/42.02
Infectious complications (BRL/EUR)	662.81/104.03	1,109.29/174.10	-446.48/70.07
Infectious complications number (by procedure)	0.17	0.29	-0.12
ICER (cost/avoided complication)	Dominant		

BRL: Brazilian real; EUR: Euro; ICER: incremental cost-effectiveness ratio.

model's results, either one at a time (deterministic) or simultaneously based on probability distributions (probabilistic). In the deterministic sensitivity analysis, the respective CIs were considered for the efficacy parameters, while a variation range of plus or minus 20 % from the baseline value was used for cost parameters. In the probabilistic sensitivity analysis, a gamma distribution was adopted for costs, as it is non-negative, and a beta distribution was used for efficacy parameters, as it is limited to values between 0 and 1 (21). All parameters of the decision tree model were evaluated in both deterministic and probabilistic sensitivity analysis. The economic analysis was conducted using Microsoft Excel, version 365 (2021).

BUDGET IMPACT ANALYSIS

A 5-year budget impact analysis was performed to understand the impact of the 5-day preoperative enteral or oral immunonutrition use for the Brazilian public healthcare system. Eligible population was estimated using an epidemiological approach and the number of patients undergoing major gastrointestinal oncologic surgeries was extracted from the public database, according to procedures described in supplementary table III (<https://www.nutricionhospitalaria.org/files/9272/ADMA1-05553-03.pdf>) (22). The number of hospitalizations for such procedures between 2015 and 2019 was used to project the estimated procedure volume for the period from 2021 to 2025 through a linear relationship between the number of procedures and the total Brazilian population (22,23) (Suppl. Table IV - <https://www.nutricionhospitalaria.org/files/9272/ADMA1-05553-03.pdf>). To determine the market share, the premise of a gradual increase in the use of oral/enteral immunonutrition was adopted after its incorporation, starting from 10 % of patients in the first year until reaching 50 % of patients in the fifth year. Costs were extracted from the economic model.

RESULTS

EFFECTIVENESS DATA

The study published by Adiamah et al. (2019) included a total of sixteen studies that assessed the use of preoperative immunonutrition among patients undergoing major gastrointestinal

surgeries, seven of them considering a 5-day period. Such studies were selected to compose this analysis and main information is shown in supplementary table V (<https://www.nutricionhospitalaria.org/files/9272/ADMA1-05553-03.pdf>).

Data related to the outcomes of interest, extracted from these seven studies, were combined and results are shown in table I. The primary outcome, infectious complications, was used to conduct the economic analysis. All studies provided data regarding infectious complications (7,24-29). The event rates of infectious complications were 17.2 % (65/378) and 28.8 % (99/344) for the immunonutrition and the control group, respectively. The pooled ORs for infectious complications after 5 days of preoperative treatment with immunonutrition was 0.46 (95 % CI, 0.28-0.78; $p = 0.003$; $I^2 = 36$ %; Fig. 1). The infectious complications OR was also evaluated according to the choice of control. When control arms received isocaloric isonitrogenous supplement (29), the OR was 0.29 (95 % CI, 0.10-0.82; $p = 0.02$; $I^2 =$ not applicable) and for those receiving no supplementation the OR was 0.50 (95 % CI, 0.28-0.90; $p = 0.02$; $I^2 = 37$ %) (7,24-28).

PARAMETERS OF THE COST-EFFECTIVENESS STUDY

The parameters, the references, the range (for the deterministic sensitivity analysis), the probability distribution, and the standard error (for the probabilistic sensitivity analysis) used in this analysis are reported in supplementary table VI (<https://www.nutricionhospitalaria.org/files/9272/ADMA1-05553-03.pdf>). The incidence of infectious and non-infectious complications and mortality within 30 days were calculated by the mean of events over the population of interest. Length of stay (mean days) was based on the WMD extracted from the meta-analysis.

INCREMENTAL COSTS AND OUTCOMES

Enteral/oral immunonutrition was dominant in relation to the standard diet (Table II). The deterministic sensitivity analysis (Fig. 2) identified the infectious complication cost and the incidence of complications in the "standard diet" group as the two

Table III. Budget impact analysis results

	2021	2022	2023	2024	2025	Total
Projected (BRL/EUR)	19,459,714/ 3,054.16	19,527,359/ 3,064.78	19,568,269/ 3,071.20	19,583,059/ 3,073.52	19,572,432/ 3,071.85	97,710,833/ 15,335.52
Reference (BRL/EUR)	19,778,384/ 3,104.18	20,177,562/ 3,166.83	20,562,164/ 3,227.19	20,932,094/ 3,285.25	21,287,344/ 3,341.01	102,737,549/ 16,124.45
Incremental (BRL/EUR)	-318,670/ -50,014.62	-650,203/ -102,048.06	-993,895/ -155,989.83	-1,349,035/ -211,728.35	-1,714,912/ -269,152.01	-5,026,715/ -788,932.87

BRL: Brazilian real; EUR: Euro.




Figure 3. Incremental cost-effectiveness plan — infectious complications avoided. A. Values presented in Brazilian reals (BRL). B. Values presented in euros (EUR).

main parameters influencing the analysis results. However, there is no potential to significantly modify the result presented in the analysis baseline scenario (dominance of immunonutrition compared to the standard diet).

Probabilistic sensitivity analysis (Fig. 3) estimated 88 % of iterations in quadrant III, in which there is lower cost and greater effectiveness. The rest of the iterations (12 %) were in quadrant II (higher cost and greater effectiveness). The most effective quadrants are quadrants II and III for this analysis, as the outcome considers the reduction of infectious complications and assumes negative values when there is greater effectiveness.

Table III shows the results of the budget impact analysis. The projected scenario considers the gradual conversion of procedures to enteral/oral immunonutrition, considering the proposed market share. Meanwhile, the reference scenario assumes that all patients do not receive a specific diet as preparation for the surgical procedure. The results indicate savings of approximately 320,000 BRL (51,816 EUR) in the first year after incorporation and a total accumulated savings over 5 years of approximately 5 million BRL (817,352 EUR). The base case scenario could vary between savings of 2.5 million and 7.5 million BRL (408,991 EUR and 1,225,713 EUR, respectively).

DISCUSSION

This analysis was performed aiming to assess the cost-effectiveness of 5-day preoperative enteral or oral immunonutrition in patients undergoing major surgery for gastrointestinal cancer. In addition, a budget impact analysis under the SUS perspective was performed. In a context of increasing costs due to the launch of new technologies in the market, there is a need to understand the relationship between costs and benefits of its use.

Initially, to support the cost-effectiveness analysis, a meta-analysis using data reported by Adiamah et al. (2019) was conducted to determine the efficacy of a prespecified period of enteral or oral immunonutrition use (8). The last ESPEN guideline, published in 2021, recommends immunonutrition, including arginine, omega-3 fatty acids and nucleotides, for five to seven days in the preoperative period, preferably for malnourished individuals but not excluding those at nutritional risk (30). The previously published review included studies that considered different durations of preoperative immunonutrition, ranging from 3 to 8 days (8). In the present analysis, the 5-day period was chosen to accomplish the ESPEN recommendation within the shortest timeframe, based on the hypothesis of a lower associated cost. Alternative durations were not assessed and should be explored in future cost-effectiveness studies.

In the present analysis, 5-day preoperative enteral or oral immunonutrition significantly reduced the occurrence of infectious complications and length of hospital stay, but statistically significant results were not found to the other outcomes (non-infectious complications and mortality). These results are similar to those reported by Adiamah et al. (2019) and also corroborate findings reported by previous meta-analyses performed to understand the impact of immunonutrition use on patients undergoing major gastrointestinal cancer surgery (8,31,32). Thus, it supports the use of immunonutrition for five days before surgical procedure.

Adiamah et al. (2019) included studies characterized as prospective randomized controlled trials that reported at least one outcome of interest in individuals aged 18 years or older undergoing surgical intervention for gastrointestinal cancer. Trials evaluating only individual components of immunonutrition, as well as those involving perioperative or postoperative administration, were excluded. No language restrictions were applied in the study (8). Furthermore, an updated literature search did not identify new evidences, supporting the assumption that all relevant studies were included in the analysis.

Only one study used standard supplementation, while most studies compared immunonutrition to a standard diet without supplements (Suppl. Table VI - <https://www.nutricionhospitalar-ia.org/files/9272/ADMA1-05553-03.pdf>). This difference may have affected the results. Therefore, it's important to consider these limitations when interpreting the findings, underscoring the need for further studies to validate these observations.

The cost-effectiveness analysis showed that enteral/oral immunonutrition was dominant in relation to the standard diet. Braga & Gianotti (2005) conducted an analysis to determine whether preoperative immunonutrition leads to cost savings in the care of patients undergoing major elective surgery to treat gastrointestinal tract neoplasms. The authors reported a mean cost of complication of 6,178 EUR in the conventional group, while this value in the group that used oral immunonutrition for 5 days before surgical procedure was 4,639 EUR. In this context, preoperative immunonutrition for 5 days has shown to be cost-effective, which is corroborated by our results (13). Ambrosio et al. (2023) analyzed the tumor microenvironment and indicators related to

immune function in 100 patients in addition to a cost-benefit analysis. They showed that immunonutrition for 14 days before surgery and 2 days after is a cost-effective strategy. The study reported that regardless of nutritional status, the immunonutrition, according to the recommendations, represented a resource after colorectal cancer surgery with an average net savings of 117,011 EUR (33). This analysis was conducted under the perspective of the SUS. To the best of authors' knowledge, this is the first study to describe the outcome considering the pre-operative period in Brazil.

Sensitivity analysis showed that infectious complication cost and the incidence of complications in the "standard diet" group are the two main parameters influencing the analysis results and that there is no potential to significantly modify the dominance of immunonutrition compared to the standard diet. Indeed, infectious complications represent an important source of cost among patients undergoing surgical treatment to manage gastrointestinal neoplasm. Zogg et al. (2018) reported, in a nationwide inpatient sample from the United States, that infectious complications was the most significant driver of increased hospital cost among patients undergoing major resections from 2001 to 2014 (34). In a recent analysis conducted in France including patients undergoing major digestive cancer surgery, individuals with infectious complications had higher hospital length of stay and cost per stay when compared to those without complications and those with other events (mean length of stay: 25.5 vs. 11.7 vs. 17.8 days; cost per stay: 18,720 EUR vs. 10,641 EUR vs. 14,636 EUR) (35).

Budget impact analysis suggests that the use of a 5-day preoperative enteral/oral immunonutrition would be able to promote savings to Brazilian healthcare system. To the best of authors' knowledge, this is the first study assessing the Brazilian context and further analysis are needed to confirm the finding. Brunton & Kerr (2022) reported that the use of perioperative immunonutrition among surgical oncology patients would be able to save about 5 million USD with a total of 100 individuals, only related to length of hospital stay (36). In the present analysis, the main effectiveness outcome used was the occurrence of infectious complications, thus savings could be even higher if other variables such as length of hospital stay were considered.

The cost-effectiveness related to immunonutrition use was also assessed in different non-oncologic settings. The use of perioperative immunonutrition has proven to be a cost-effective strategy among patients undergoing surgical procedures. Gianotti et al. (2000) reported a net saving of 2,386 EUR per complication avoided (37). Among critically ill patients, the use of immunonutrition has shown a reduction in the occurrence of nosocomial pneumonia and by reducing intensive care unit stay, a cost saving of at least 193,350.00 USD (38).

In spite of these important contributions, our study has limitations that need to be highlighted. In addition, most of the studies compared immunonutrition against no intervention and this is a matter of concern since cancer patients report clusters of symptoms that may be related to low nutrient intake and weight loss (39). However, nutritional status prior to surgery reported through mean BMI was similar in intervention and control groups in the

included studies, which may reduce the impact of such limitation. Furthermore, the use of random effects model to parametrize the effect of the intervention in the cost-effectiveness model, with its broader confidence interval, was considered a conservative approach to deal with the uncertainty within the model and reduced the impact of the aforementioned limitation. Although only oncologic surgical populations were assessed in the analysis, the results may be generalized to non-oncologic surgical populations, as the outcomes are relevant to both. Regarding the cost-effectiveness analysis, some information is derived from key-opinion leaders or premises, imposing uncertainties, and it was conducted under the SUS perspective and may not be representative of the whole Brazilian healthcare system. The absence of Brazilian data may also limit the translation of the results to the healthcare setting of the country. Also, it is important to note that the modelling was not based on quality-adjusted life years (QALY), which is a preferred outcome for cost-effectiveness analysis. Instead, the analysis was based on clinical outcomes (infectious complications avoided), which is a more tangible outcome for decision makers, but can be limiting for broader policy comparisons. Previously published studies assessing the cost-effectiveness related to the use of immunonutrition also considered measures from clinical practice (37,38).

CONCLUSIONS

The results suggest that 5-day preoperative enteral or oral immunonutrition not only has a positive clinical impact on patients since it is effective to prevent infectious complications and decreases hospital length of stay among patients undergoing major surgery for gastrointestinal cancer, but can also generate substantial reductions in costs. The data provided in the present analysis is helpful to support decision making in the management of patients with the diagnosis of gastrointestinal cancer.

REFERENCES

1. Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S, et al. ESPEN practical guideline: Clinical nutrition in surgery. *Clin Nutr* 2021;40(7):4745-61. DOI: 10.1016/j.clnu.2021.03.031
2. Page F, Winstone J. Better care through better nutrition : Value and effects of Medical Nutrition: A summary of the evidence base. Medical Nutrition International Industry; 2018.
3. Wischmeyer PE, Carli F, Evans DC, Guilbert S, Kozar R, Pryor A, et al. American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on Nutrition Screening and Therapy Within a Surgical Enhanced Recovery Pathway. *Anesth Analg* 2018;126(6):1883-95. DOI: 10.1213/ANE.0000000000002743
4. Akyuz EY, Akyuz C, Kiziltan G, Sehirli AO, Cetinel S. The effects of oral nutritional formula enriched with arginine, omega 3 fatty acids and nucleotides on methotrexate-induced experimental intestinal mucositis. *J Nutr Intern Med* 2018;20(2):248-56. DOI: 10.23751/pn.v20i2.6396
5. Kemen M, Senkal M, Homann HH, Mumme A, Dauphin AK, Baier J, et al. Early postoperative enteral nutrition with arginine-omega-3 fatty acids and ribonucleic acid-supplemented diet versus placebo in cancer patients. *Crit Care Med* 1995;23(4):652-9. DOI: 10.1097/00003246-199504000-00012
6. Daly JM, Lieberman MD, Goldfine J, Shou J, Weintraub F, Rosato EF, et al. Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids

- in patients after operation: immunologic, metabolic, and clinical outcome. *Surgery* 1992;112(1):56-67.
7. Gianotti L, Braga M, Nespoli L, Radaelli G, Beneduce A, Di Carlo V. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. *Gastroenterology* 2002;122(7):1763-70. DOI: 10.1053/gast.2002.33587
 8. Adiamah A, Skořepa P, Weimann A, Lobo DN. The Impact of Preoperative Immune Modulating Nutrition on Outcomes in Patients Undergoing Surgery for Gastrointestinal Cancer: A Systematic Review and Meta-analysis. *Ann Surg* 2019;270(2):247-56. DOI: 10.1097/SLA.0000000000003256
 9. Song GM, Liu XL, Bian W, Wu J, Deng YH, Zhang H, et al. Systematic review with network meta-analysis: comparative efficacy of different enteral immunonutrition formulas in patients underwent gastrectomy. *Oncotarget* 2017;8(14):23376-88. DOI: 10.18632/oncotarget.15580
 10. Hegazi RA, Hustead DS, Evans DC. Preoperative standard oral nutrition supplements vs immunonutrition: Results of a systematic review and meta-analysis. *J Am Coll Surg* 2014;219(5):1078-87. DOI: 10.1016/j.jamcollsurg.2014.06.016
 11. Reis A, Kabke G, Fruchtenicht A, Barreiro T, Moreira L. Custo benefício da imunonutrição perioperatória em cirurgia oncológica do trato gastrointestinal: uma revisão sistemática. *ABCD Arq Bras Cir Dig* 2016;29(2):121-5.
 12. Pimiento JM, Evans DC, Tyler R, Barrocas A, Hernandez B, Araujo-Torres K, et al. Value of nutrition support therapy in patients with gastrointestinal malignancies: A narrative review and health economic analysis of impact on clinical outcomes in the United States. *J Gastrointest Oncol* 2021;12(2):864-73. DOI: 10.21037/jgo-20-326
 13. Braga M, Gianotti L. Preoperative immunonutrition: Cost-benefit analysis. *J Parenter Enter Nutr* 2005;29(SUPPL. 1). DOI: 10.1177/01486071050290s1s57
 14. Bozeman MC, Schott LL, Desai AM, Miranowski MK, Baumer DL, Lowen CC, et al. Healthcare Resource Utilization and Cost Comparisons of High-Protein Enteral Nutrition Formulas Used in Critically Ill Patients. *J Heal Econ Outcomes Res* 2022;9(2):1-10. DOI: 10.36469/jheor.2022.36287
 15. Banerjee S, Garrison LP, Danel A, Ochoa Gautier JB, Flum DR. Effects of arginine-based immunonutrition on inpatient total costs and hospitalization outcomes for patients undergoing colorectal surgery. *Nutrition* 2017;42:106-13. DOI: 10.1016/j.nut.2017.06.002
 16. Mauskopf JA, Candrilli SD, Chevrou-Séverac H, Ochoa JB. Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costs. *World J Surg Oncol* 2012;10(1):136. DOI: 10.1186/1477-7819-10-136
 17. Ministério da Saúde (BR). Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Estimativa 2023: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2022. p. 156. Available from: <https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2023.pdf>
 18. Torres U dos S, Almeida TEP de, Netinho JG. Increasing hospital admission rates and economic burden for colorectal cancer in Brazil, 1996-2008. *Rev Panam Salud Pública* 2010;28(4):244-8. DOI: 10.1590/S1020-49892010001000002
 19. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., editors. *Cochrane Handbook for Systematic Reviews of Interventions* version 6.1 (updated September 2020). [Internet]. Available from: www.training.cochrane.org/handbook.
 20. The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.4. 2020.
 21. Briggs A, Sculpher M, Claxton K. *Decision Modelling for Health Economic Evaluation*. Oup Oxford; 2006.
 22. Ministério da Saúde (Brasil). Departamento de Informática do SUS (DATASUS). Informações de Saúde (TABNET) [Internet]. Brasília, DF: Ministério da Saúde; 2020. Available from: http://tabnet.datasus.gov.br/cgi/menu_tabnet.php.htm
 23. Instituto Brasileiro de Geografia e Estatística (IBGE). *Projeção da População do Brasil por sexo e idade: 2010-2060 - Revisão 2018* [Internet]. Rio de Janeiro: IBGE; 2018. Available from: <https://www.ibge.gov.br/estatisticas/sociais/populacao/9103-estimativas-de-populacao.html?edicao=22367&t=resultados>
 24. Aida T, Furukawa K, Suzuki D, Shimizu H, Yoshidome H, Ohtsuka M, et al. Preoperative immunonutrition decreases postoperative complications by modulating prostaglandin E2 production and T-cell differentiation in patients undergoing pancreatoduodenectomy. *Surg (United States)* 2014;155(1):124-33. DOI: 10.1016/j.surg.2013.05.040
 25. Moriya T, Fukatsu K, Okamoto K, Shinto E, Ueno H, Hasel K, et al. LB022-SUN: Effects of Preoperative use of an Immune-Enhancing Diet on Postoperative Complications and Long-Term Outcome: A Randomized Clinical Trial in Colorectal Cancer Surgery in Japanese Patients. *Clin Nutr* 2014;33(1):S247. DOI: 10.1016/S0261-5614(14)50648-6
 26. Fujitani K, Tsujinaka T, Fujita J, Miyashiro I, Imamura H, Kimura Y, et al. Prospective randomized trial of preoperative enteral immunonutrition followed by elective total gastrectomy for gastric cancer. *Br J Surg* 2012;99(5):621-9. DOI: 10.1002/bjs.8706
 27. Mikagi K, Kawahara R, Kinoshita H, Aoyagi S. Effect of Preoperative Immunonutrition in Patients Undergoing Hepatectomy: A Randomized Controlled Trial. *Kurume Med J* 2011;58(1):1-8. DOI: 10.2739/kurumemedj.58.1
 28. Nakamura K, Kariyazono H, Komokata T, Hamada N, Sakata R, Yamada K. Influence of preoperative administration of ω -3 fatty acid-enriched supplement on inflammatory and immune responses in patients undergoing major surgery for cancer. *Nutrition* 2005;21(6):639-49. DOI: 10.1016/j.nut.2005.03.001
 29. Braga M, Gianotti L, Vignali A, Di Carlo V. Preoperative oral arginine and *n*-3 fatty acid supplementation improves the immunometabolic host response and outcome after colorectal resection for cancer. *Surgery* 2002;132(5):805-14. DOI: 10.1067/msy.2002.128350
 30. Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S, et al. ESPEN practical guideline: Clinical nutrition in surgery. *Clin Nutr* 2021;40(7):4745-61. DOI: 10.1016/j.clnu.2021.03.031
 31. Song GM, Tian X, Zhang L, Ou YX, Yi LJ, Shuai T, et al. Immunonutrition support for patients undergoing surgery for gastrointestinal malignancy: Preoperative, postoperative, or Perioperative a Bayesian network meta-Analysis of randomized controlled trials. *Med (United States)* 2015;94(29). DOI: 10.1097/MD.0000000000001225
 32. Song GM, Liu XL, Bian W, Wu J, Deng YH, Zhang H, et al. Systematic review with network meta-analysis: Comparative efficacy of different enteral immunonutrition formulas in patients underwent gastrectomy. *Oncotarget* 2017;8(14):23376-88. DOI: 10.18632/oncotarget.15580
 33. Ambrosio MR, Spagnoli L, Perotti B, Petrelli F, Caimi S, Saieva C, et al. Paving the Path for Immune Enhancing Nutrition in Colon Cancer: Modulation of Tumor Microenvironment and Optimization of Outcomes and Costs. *Cancers (Basel)* 2023;15(2):437. DOI: 10.3390/cancers15020437
 34. Zogg CK, Ottesen TD, Kebaish KJ, Galivanche A, Murthy S, Changoor NR, et al. The Cost of Complications Following Major Resection of Malignant Neoplasia. *J Gastrointest Surg* 2018;22(11):1976-86. DOI: 10.1007/s11605-018-3850-6
 35. Piessen G, Dive-Pouletty C, Danel A, Laborey M, Thomé B. Clinical and economic burden of surgical complications during hospitalization for digestive cancer surgery in France. *Cancer Rep* 2023;6(12). DOI: 10.1002/cnr2.1895
 36. Brunton C, Kerr K. Budget Impact Analysis of Perioperative Nutrition in Surgical Oncology Patients. *Value Heal* 2022;25(12):S148-9. DOI: 10.1016/j.jval.2022.09.718
 37. Gianotti L, Braga M, Frei A, Greiner R, Di Carlo V. Health care resources consumed to treat postoperative infections: cost saving by perioperative immunonutrition. *Shock* 2000;14(3):325-30. DOI: 10.1097/00024382-200014030-00015
 38. Farber MS, Moses J, Korn M. Reducing Costs and Patient Morbidity in the Enterally Fed Intensive Care Unit Patient. *J Parenter Enter Nutr* 2005;29(1S). DOI: 10.1177/01486071050290S1S62
 39. Roxburgh CSD, McMillan DC. Cancer and systemic inflammation: Treat the tumour and treat the host. *Br J Cancer* 2014;110(6):1409-12. DOI: 10.1038/bjc.2014.90